<DOC>
	<DOC>NCT00750841</DOC>
	<brief_summary>Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.</brief_summary>
	<brief_title>Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Written informed consent Prostate cancer), which is refractory to standard therapies or for which no standard therapy exists. Estimated life expectancy of at least 8 weeks WHO performance status (PS) 02. Unstable brain/meningeal metastases Biochemistry/haematology results outside of required ranges History of significant GI impairment Inadequate bone marrow reserve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>advanced cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>rifampicin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>Advanced solid tumours</keyword>
</DOC>